Amit Garg, MD, discusses 3-year pooled BE HEARD safety data on bimekizumab in moderate to severe hidradenitis suppurativa from EADV 2026.
Amit Garg, MD
Advertisement
Professor and the Founding Chair for the Department of Dermatology at the Donald and Barbara Zucker School of Medicine at Hofstra / Northwell
Articles by Amit Garg, MD
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on HCPLive
1
Resmetirom Tied to Lower MACE vs Semaglutide in Real-World MASLD Analysis
2
Eplontersen Fails to Achieve Primary Endpoint, Improves KCCQ and 6MWT in ATTR-CM
3
Dupilumab Improves Esophageal Distensibility in EoE: REMODEL Trial
4
Tovinontrine 50 mg Improves cGMP With Minimal Effect on NT-proBNP in HFpEF
5